No Data
No Data
"Going global" and "innovation" are the key words that cannot be bypassed. Sun Piaoyang from Jiangsu Hengrui Pharmaceuticals, Zhu Yi from Baheal Pharm and other top pharmaceutical industry leaders jointly discuss the next decade | Industry Observation
On November 14, 2024, the opening ceremony of the Insight Conference was held in Chengdu, where experts in the pharmaceutical industry, investors, and chairmen of top listed companies exchanged views on the challenges and opportunities facing the China meheco group. The two key themes of "going global" and "innovation" ran through the entire conference. Faced with the question of the future direction of innovative drugs in China, various enterprises also provided different answers.
Reports suggest that the Trump team plans to cancel the $7,500 tax credit for electric autos, leading to a sharp drop in electric car stocks.
The Trump team is considering canceling the $7,500 electric vehicle subsidy policy to fund its tax reduction plan. This policy is one of the measures adopted by the Biden administration to combat inflation. Trump supporters and the oil industry hope to cancel electric vehicle tax incentives, while the auto industry groups are calling for retention. Musk believes that canceling the subsidy policy will not have a significant impact on Tesla, but will rather cause more trouble for competitors. Electric vehicle stocks plummet, with Tesla down 5.77% and "Tesla rival" Rivian down 14.3%.
Ningde Zeng Yuqun: Musk does not understand batteries, the "zero carbon" power grid will be ten times larger than the electric vehicle battery business.
Musk's bet on cylindrical batteries (i.e., 4680) "will fail and will never succeed." "We had a very intense debate. He (Musk) was silent because he did not know how to manufacture the battery. This is about electrochemistry, and he is good at chips, software, hardware, and machinery."
The biggest dark horse of the car circle was born this year.
Charge towards the giants.
Shunfeng steps on the accelerator for overseas expansion.
One step away from the Hong Kong IPO.
byd company limited firmly holds the iron throne
Intensifying competition.
GinLex : I think is normal practice, isn't it? To price in line to the NAV, else the premium too high or too low.
Correct me if I am wrong.